{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:47:54Z","timestamp":1789678074243,"version":"4.0.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","heartfailure.onlinejacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jchf.2019.01.009","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T16:51:00Z","timestamp":1551113460000},"page":"258-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Adverse Drug Reactions to Guideline-Recommended Heart\u00a0Failure\u00a0Drugs in Women"],"prefix":"10.1016","volume":"7","author":[{"given":"Sophie H.","family":"Bots","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor","family":"Groepenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk L.M.","family":"Eikendal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Tannenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula A.","family":"Rochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Regitz-Zagrosek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W.","family":"Asselbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester M.","family":"den Ruijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2019.01.009_bib1","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/eurheartj\/ehv161","article-title":"Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC","volume":"36","author":"Rosano","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.01.009_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jchf.2019.01.009_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1517\/14740338.2014.947260","article-title":"Adherence to therapy and adverse drug reactions: is there a link?","volume":"13","author":"Leporini","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jchf.2019.01.009_bib4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-008-0494-6","article-title":"Women encounter ADRs more often than do men","volume":"64","author":"Zopf","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jchf.2019.01.009_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/CIRCOUTCOMES.110.868307","article-title":"Representation of women in randomized clinical trials of cardiovascular disease prevention","volume":"3","author":"Melloni","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jchf.2019.01.009_bib6","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.jacc.2018.02.070","article-title":"Participation of women in clinical trials supporting FDA approval of cardiovascular drugs","volume":"71","author":"Scott","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.01.009_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamacardio.2018.2559","article-title":"Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review","volume":"3","author":"Tahhan","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2019.01.009_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1089\/jwh.2008.0971","article-title":"Participation of women in clinical trials for new drugs approved by the Food and Drug Administration in 2000\u20132002","volume":"18","author":"Yang","year":"2009","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.jchf.2019.01.009_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.jchf.2019.01.009_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjmed.2014.08.024","article-title":"Multimorbidity in heart failure: a community perspective","volume":"128","author":"Chamberlain","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2019.01.009_bib11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11897-014-0186-8","article-title":"Polypharmacy in heart failure patients","volume":"11","author":"Mastromarino","year":"2014","journal-title":"Currt Heart Fail Rep"},{"key":"10.1016\/j.jchf.2019.01.009_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11936-018-0687-y","article-title":"Sex differences in the management of advanced heart failure","volume":"20","author":"Crousillat","year":"2018","journal-title":"Curr Treat Options Cardiovascr Med"},{"key":"10.1016\/j.jchf.2019.01.009_bib13","first-page":"iii14","article-title":"Gender and heart failure: a population perspective","volume":"92 Suppl 3","author":"Mehta","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2019.01.009_bib14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ejheart.2007.02.001","article-title":"Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure \u2014 a population study","volume":"9","author":"Hudson","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.01.009_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.118.037585","article-title":"Recommended heart failure medication and adverse drug reactions in women: a call for sex-specific data reporting.","author":"Bots","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2019.01.009_bib16","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.01.009_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40256-017-0256-x","article-title":"A\u00a0database cohort study to assess the risk of angioedema among patients with heart failure initiating angiotensin-converting enzyme inhibitors in the USA","volume":"18","author":"Do","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jchf.2019.01.009_bib18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0002-8703(96)90365-8","article-title":"Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"131","author":"Kostis","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2019.01.009_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0002-8703(94)90490-1","article-title":"Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction","volume":"128","author":"Kostis","year":"1994","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2019.01.009_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijcard.2008.03.063","article-title":"Enalapril-induced cough is associated with non-severe heart failure","volume":"135","author":"Sadanaga","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2019.01.009_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2004.10.038","article-title":"Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction","volume":"45","author":"Ishani","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.01.009_bib22","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.01.009_bib23","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurjhf\/hfs145","article-title":"Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial","volume":"14","author":"Kiernan","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.01.009_bib24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0735-1097(98)00680-9","article-title":"Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure","volume":"33","author":"Macdonald","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.01.009_bib25","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa021266","article-title":"Sex-based differences in the effect of digoxin for the treatment of heart failure","volume":"347","author":"Rathore","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.01.009_bib26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/CIRCOUTCOMES.111.000079","article-title":"Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure","volume":"6","author":"Freeman","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jchf.2019.01.009_bib27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/clc.20284","article-title":"Safety of spironolactone use in ambulatory heart failure patients","volume":"31","author":"Lopes","year":"2008","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jchf.2019.01.009_bib28","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jacc.2018.02.069","article-title":"Participation of women in clinical trials: not yet time to rest on our laurels","volume":"71","author":"Pilote","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.01.009_bib29","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1111\/jgs.15020","article-title":"Systematic review of sex-specific reporting of data: cholinesterase inhibitor example","volume":"65","author":"Mehta","year":"2017","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jchf.2019.01.009_bib30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2008.05.025","article-title":"Enrollment of women in National Heart, Lung, and Blood Institute-funded cardiovascular randomized controlled trials fails to meet current federal mandates for inclusion","volume":"52","author":"Kim","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.01.009_bib31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ehf2.12307","article-title":"Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines","volume":"5","author":"Levinsson","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2019.01.009_bib32","first-page":"321","article-title":"Reporting of gender-related information in clinical trials of drug therapy for myocardial infarction","volume":"159","author":"Rochon","year":"1998","journal-title":"CMAJ"},{"key":"10.1016\/j.jchf.2019.01.009_bib33","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jchf.2019.01.009_bib34","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.3399\/bjgp17X690533","article-title":"Comorbidity and polypharmacy in chronic heart failure: a large cross-sectional study in primary care","volume":"67","author":"Baron-Franco","year":"2017","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.jchf.2019.01.009_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1300\/J074v13n04_04","article-title":"A\u00a0prediction model for polypharmacy: are older, educated women more susceptible to an adverse drug event?","volume":"13","author":"Perry","year":"2001","journal-title":"J\u00a0Women Aging"},{"key":"10.1016\/j.jchf.2019.01.009_bib36","first-page":"187103","article-title":"Sex differences in drug disposition","volume":"2011","author":"Soldin","year":"2011","journal-title":"J\u00a0Biomed Biotechnol"},{"key":"10.1016\/j.jchf.2019.01.009_bib37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tips.2009.12.001","article-title":"Gender differences in drug toxicity","volume":"31","author":"Nicolson","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jchf.2019.01.009_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijcard.2018.04.102","article-title":"Patient reported outcome in HFpEF: Sex-specific differences in quality of life and association with outcome","volume":"267","author":"Faxen","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2019.01.009_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejheart.2006.10.012","article-title":"Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM","volume":"9","author":"Lewis","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.01.009_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejcnurse.2005.04.011","article-title":"Factors and interventions influencing health-related quality of life in patients with heart failure: a review of the literature","volume":"5","author":"Johansson","year":"2006","journal-title":"Eur J Cardiovasc Nurs"},{"key":"10.1016\/j.jchf.2019.01.009_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrtlng.2018.09.009","article-title":"Relationship of medication adherence and quality of life among heart failure patients","author":"Silavanich","year":"2018","journal-title":"Heart Lung"},{"key":"10.1016\/j.jchf.2019.01.009_bib42","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(05)67760-4","article-title":"Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial","volume":"366","author":"Granger","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2019.01.009_bib43","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1001\/archinte.1989.00390120061012","article-title":"Enalapril-induced cough","volume":"149","author":"Gibson","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jchf.2019.01.009_bib44","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/000331979404500908","article-title":"ACE inhibitors and cough","volume":"45","author":"Yesil","year":"1994","journal-title":"Angiology"},{"key":"10.1016\/j.jchf.2019.01.009_bib45","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1136\/bmj.294.6586.1521","article-title":"Cough associated with captopril and enalapril","volume":"294","author":"Coulter","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jchf.2019.01.009_bib46","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1053\/meta.2001.27212","article-title":"Angiotensin-converting enzyme gene insertion\/deletion, not bradykinin B2 receptor -58T\/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus","volume":"50","author":"Lee","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.jchf.2019.01.009_bib47","first-page":"141","article-title":"High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese","volume":"40","author":"Woo","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jchf.2019.01.009_bib48","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","author":"Miller","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2019.01.009_bib49","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jaip.2017.02.018","article-title":"Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record","volume":"5","author":"Banerji","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jchf.2019.01.009_bib50","doi-asserted-by":"crossref","first-page":"e000888","DOI":"10.1136\/bmjopen-2012-000888","article-title":"Observational cohort study of the safety of digoxin use in women with heart failure","volume":"2","author":"Flory","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.jchf.2019.01.009_bib51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ejheart.2005.10.002","article-title":"Serum digoxin concentration and outcomes in women with heart failure: a bi-directional effect and a possible effect modification by ejection fraction","volume":"8","author":"Ahmed","year":"2006","journal-title":"Eur Heart Fail"},{"key":"10.1016\/j.jchf.2019.01.009_bib52","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrendo.2014.139","article-title":"Gynaecomastia\u2014pathophysiology, diagnosis and treatment","volume":"10","author":"Narula","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jchf.2019.01.009_bib53","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11897-017-0341-0","article-title":"Treatment of hyperkalemia in heart failure","volume":"14","author":"DeFilippis","year":"2017","journal-title":"Curr Heart Fail Rep"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177919300307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177919300307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:23:46Z","timestamp":1574083426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177919300307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2213177919300307"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2019.01.009","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Drug Reactions to Guideline-Recommended Heart\u00a0Failure\u00a0Drugs in Women","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2019.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}